Michael C Haffner
Overview
Explore the profile of Michael C Haffner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
3891
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kumaraswamy A, Mannan R, Swaim O, Rodansky E, Wang X, Udager A, et al.
Neoplasia
. 2025 Mar;
63:101151.
PMID: 40088674
Background: Lysine-specific demethylase 1 (LSD1) is a histone demethylase and regulator of differentiation, including in cancer. A neuronal-specific isoform of LSD1-LSD1+8a-has been shown to play a key role in promoting...
2.
Li S, Song K, Sun H, Tao Y, Huang A, Bhatia V, et al.
bioRxiv
. 2025 Mar;
PMID: 40027790
Neuroendocrine prostate cancer (NEPC) arises primarily through neuroendocrine transdifferentiation (NEtD) as an adaptive mechanism of therapeutic resistance. Models to define the functional effects of putative drivers of this process on...
3.
Raychaudhuri R, Tuchayi A, Low S, Arafa A, Graham L, Gulati R, et al.
Eur Urol Oncol
. 2025 Feb;
PMID: 39920014
Background And Objective: The prostate-specific membrane antigen (PSMA) radioligand Lu-PSMA-617 (LuPSMA) is approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). PARP inhibitors (PARPi) are approved for patients with mCRPC...
4.
Haffner M, Morris M, Ding C, Sayar E, Mehra R, Robinson B, et al.
Clin Cancer Res
. 2024 Nov;
31(3):466-478.
PMID: 39589343
Lineage plasticity and histologic transformation from prostate adenocarcinoma to neuroendocrine (NE) prostate cancer (NEPC) occur in up to 15% to 20% of patients with castration-resistant prostate cancer (CRPC) as a...
5.
Zhao Y, Gulati R, Yang Z, Newcomb L, Zheng Y, Zhu K, et al.
J Natl Cancer Inst
. 2024 Nov;
PMID: 39565901
Background: Implications of relabeling grade group (GG) 1 prostate cancer as non-cancer will depend on the recommended active surveillance (AS) strategy. Whether relabeling should prompt de-intensifying, PSA-based active monitoring approaches...
6.
Demirci R, Ghodsi A, Gulati R, Behnia S, Nelson P, Cheng H, et al.
J Nucl Med
. 2024 Nov;
66(1):47-53.
PMID: 39542703
The VISION and TheraP trials introduced different PET-based criteria for patient selection for treatment with Lu-PSMA-617 (LuPSMA). TheraP used a higher prostate-specific membrane antigen (PSMA) uptake threshold than VISION and...
7.
Demirci R, Gulati R, Hawley J, Yezefski T, Haffner M, Cheng H, et al.
J Nucl Med
. 2024 Nov;
65(12):1945-1951.
PMID: 39510589
Lu-PSMA-617 (LuPSMA) is a newly established treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), but survival outcomes vary widely, and predictors of treatment responses are needed. This study investigated...
8.
Armstrong A, Taylor A, Haffner M, Abida W, Bryce A, Karsh L, et al.
Prostate Cancer Prostatic Dis
. 2024 Oct;
PMID: 39354185
Background/objectives: Unfortunately, not all metastatic castration resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine...
9.
Serritella A, Taylor A, Haffner M, Abida W, Bryce A, Karsh L, et al.
Prostate Cancer Prostatic Dis
. 2024 Sep;
PMID: 39333696
Background/objectives: Unfortunately, not all metastatic castration-resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic...
10.
Frank S, Persse T, Coleman I, Bankhead 3rd A, Li D, De-Sarkar N, et al.
bioRxiv
. 2024 Jul;
PMID: 39071291
Genomic loss of the transcriptional kinase occurs in ~6% of metastatic castration-resistant prostate cancers (mCRPC) and correlates with poor patient outcomes. Prior studies demonstrate that acute CDK12 loss confers a...